From:  Unexpected “Lazarus response” to single-agent bevacizumab in heavily pretreated patients with HER2-positive breast cancer
 

Brief description of the treatment for the patients receiving bevacizumab monotherapy

PatientAgeIHC detectionDate of breast cancer diagnosisNeoadjuvant therapySurgeryDuration of relapse-free interval, monthsDate of the detection of metastatic diseaseConventional treatment of metastatic diseaseDate of bevacizumab monotherapy administrationMain benefit from bevacizumab, its durationSurvival after the start of bevacizumab, months
Patient 154 yearsER–/PR–/HER2+++August 2019Doxo + Cyclo, Tax + Trast + PertMarch 202019September 2021Carbo + Tax + Trast + Pert, Trast + Pert, Lapa + CapeSeptember 2022Immediate resolution of coma, 3.5 months6
Patient 268 yearsER+/PR–/HER2+++April 2017***April 2017Doxo + Cyclo, Tax, Carbo + Tax + Trast + Zole, Cape, anastrozole, Tax + Trast + Pert, Trast + Pert, Lapa + Trast, T-DM1September 2022Immediate resolution of neurological symptoms, 3.5 months12+
Patient 352 yearsER+/PR–/HER2+++December 2015Cyclo + mitoxantrone + 5-FUMarch 201627June 2018T-DM1, WBRT, Carbo + Tax + Trast + Pert, Trast + Pert, RS, Trast + PertDecember 2022Partial response, 9+ months9+
Patient 462 yearsER–/PR–/HER2+++May 2011NoneMay 201168January 2017Tax + Trast, Trast, Carbo + Cape + Trast, Lapa + Cape, T-DM1, Carbo + Tax + Trast + Pert, Trast + Pert, eribulin + Trast, Lapa + Cape, Lapa + TrastSeptember 2021Immediate restoration of normal breathing, regression of superficial neck metastases; the duration of the effect could not be estimated because paclitaxel was added starting from the 2nd cycle5 (death from sepsis)
Return to article view

* Not applicable: initially metastatic disease. IHC: immunohistochemistry; RS: radiosurgery; Doxo: doxorubicin; Cyclo: cyclophosphamide; Tax: taxanes; Trast: trastuzumab; Pert: pertzumab; Carbo: carboplatin; Lapa: labatinib; Cape: capecitabine; Zole: zoledronic acid; 5-FU: 5-fluorouracil; WBRT: whole-brain radiotherapy